University of Belgrade, School of Medicine, Clinic for Gynecology and Obstetrics, Clinical Centre of Serbia, Koste Todorovica 26, 11000 Belgrade, Serbia.
J Clin Endocrinol Metab. 2012 Nov;97(11):4014-21. doi: 10.1210/jc.2012-1392. Epub 2012 Sep 4.
Fetuses from mothers with autoimmune thyroid disease (AITD) may be affected by antithyroid antibodies, antithyroid drugs, and iodine.
The study correlated fetal free T(4) (fT4) with fetal ultrasound parameters and maternal thyroid function, thyroid antibodies, and medication dose from mothers with AITD.
The study was designed as a prospective cohort study and conducted in an academic referral center.
Eighty-three of 85 women with AITD completed the study; 38 were treated for hyperthyroidism and 25 for hypothyroidism, and 20 were euthyroid.
Outcomes were as follows: 1) fetal-fT4, TSH, ultrasound parameters (morphology, biometrics, heart rate); and 2) maternal-fT4, TSH, antithyroid drug dose, and antithyroid antibodies, thyroid peroxidase and TSH receptor (TRAK). Parameters were determined at the same time, between the 22nd and 33rd wk gestation.
A total of 48.3% of fetuses from hyperthyroid mothers, 60% of fetuses from hypothyroid mothers, and 10% of fetuses from euthyroid mothers had elevated fT4 levels (P = 0.006). In hypothyroid mothers, the presence of both thyroid antibodies was related to fetal hyperthyroidism, whereas absence was related to fetal euthyroidism (P = 0.019). Hyperthyroid mothers (TRAK-positive, thyroid peroxidase-negative) with hyperthyroid fetuses had significantly higher mean TRAK than hyperthyroid mothers with euthyroid fetuses (13.7 vs. 3.7 IU/liter; P = 0.02). Fetal fT4 correlated weakly negatively with maternal TSH within the normal range, but not with ultrasound parameters or with antithyroid drug dose.
High fetal fT4 levels were unexpectedly frequent in women with AITD, including maternal autoimmune hypo- and hyperthyroidism. Further studies are needed, as well as noninvasive methods to assess fetal thyroid function.
患有自身免疫性甲状腺疾病(AITD)的孕妇的胎儿可能会受到抗甲状腺抗体、抗甲状腺药物和碘的影响。
本研究旨在探讨 AITD 孕妇的胎儿游离 T4(fT4)与胎儿超声参数以及母体甲状腺功能、甲状腺抗体和药物剂量之间的相关性。
本研究设计为前瞻性队列研究,在学术转诊中心进行。
85 名患有 AITD 的女性中,有 83 名完成了研究;38 名患有甲状腺功能亢进症,25 名患有甲状腺功能减退症,20 名甲状腺功能正常。
结果如下:1)胎儿 fT4、TSH、超声参数(形态、生物计量学、心率);2)母体 fT4、TSH、抗甲状腺药物剂量、抗甲状腺抗体、甲状腺过氧化物酶和促甲状腺素受体(TRAK)。参数在妊娠 22 至 33 周时同时确定。
甲状腺功能亢进症孕妇的胎儿中,有 48.3%的胎儿 fT4 水平升高,甲状腺功能减退症孕妇的胎儿中有 60%的胎儿 fT4 水平升高,甲状腺功能正常孕妇的胎儿中有 10%的胎儿 fT4 水平升高(P=0.006)。在甲状腺功能减退症孕妇中,两种甲状腺抗体均存在与胎儿甲状腺功能亢进有关,而不存在与胎儿甲状腺功能正常有关(P=0.019)。甲状腺功能亢进症孕妇(TRAK 阳性,甲状腺过氧化物酶阴性)的胎儿甲状腺功能亢进症发生率明显高于甲状腺功能正常孕妇(13.7 比 3.7 IU/L;P=0.02)。胎儿 fT4 与母体正常范围内的 TSH 呈弱负相关,但与超声参数或抗甲状腺药物剂量无关。
AITD 孕妇,包括自身免疫性甲状腺功能减退症和甲状腺功能亢进症孕妇,胎儿 fT4 水平升高的情况出乎意料地频繁。需要进一步研究,并需要寻找评估胎儿甲状腺功能的非侵入性方法。